CereVasc Announces FDA Approval of Second IDE Study of the eShunt(R) System

US Based Pilot Study to enroll patients who develop communicating hydrocephalus following subarachnoid hemorrhage BOSTON, Aug. 9, 2022 -- (Healthcare Sales & Marketing Network) -- CereVasc, Inc., a privately held, clinical-stage, medical device company... Devices, Neurosurgery, Interventional, FDA CereVasc , eShunt System, hydrocephalus
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news